Ranbaxy Laboratories In Tie-Up For Generic Of Novartis AG's Diovan, If Approved, Ranbaxy Could Grab 50 Percent Of Its $1.5 Billion Market

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Drug maker Ranbaxy Laboratories is learnt to have partnered another multinational pharmaceuticals company for sourcing active pharmaceutical ingredients, or API, for the generic version of anti-hypertension drug Diovan. Sources said the company had already filed an application with the US regulator, seeking permission for the partnership. A detailed email questionnaire sent to Ranbaxy on Monday did not elicit any response.

Help employers find you! Check out all the jobs and post your resume.

Back to news